Total
0
Shares
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating - The Market Herald
CEO & Managing Director, Dr Tony Keating
Source: Courier Mail
  • ResApp Health (RAP) has launched its respiratory diagnostic test, ResAppDx, on select Android devices
  • This launch follows thorough testing, and the app is now available on the Samsung Galaxy S9, S10 and S20 devices
  • This testing was designed to ensure ResAppDx's algorithms had the required level of accuracy for each make and model of the phone
  • ResAppDx uses machine learning algorithms to analyse a patients cough sounds to diagnose disease and provide quick and accurate information
  • ResApp is now in the process of launching ResAppDx for Android through its existing partners and further launches on other devices are planned for the near-term
  • Company shares up 9.52 per cent on the market this morning and are trading for 11.5 cents each

ResApp Health (RAP) has launched its respiratory diagnostic test, ResAppDx, on select Android devices.

This launch follows thorough testing, and the app is now available on the Samsung Galaxy S9, S10 and S20 devices.

This testing was designed to ensure that ResAppDx's algorithms had the required level of accuracy for each make and model of the phone.

Multiple new testing procedures and algorithms were needed to ensure the test would be perform similar on each device.

ResApp is now in the process of launching ResAppDx for Android through its existing partners and further launches on other devices are planned for the near-term.

"Launching ResAppDx on select Android devices is a major achievement for ResApp. The company has undertaken extensive testing to ensure our offering continues to meet the high standards set by regulative bodies and provides clinicians with best in class solution to test for respiratory disease," CEO and Managing Director Dr Tony Keating said.

"We anticipate that the launch for Android users will considerably broaden our potential patient base and look forward to launching SleepCheck for Android," he added.

ResAppDx is ResApp's mobile software app which is used by clinicians for the diagnosis of multiple respiratory problems.

It uses machine learning algorithms to analyse a patient's cough sounds and diagnose the disease and provide quick and accurate information.

It is a software-only solution that runs on smartphones, meaning it does not require any additional hardware or accessories.

ResApp is up 9.52 per cent on the market this morning with shares trading for 11.5 cents each at 11:24 am AEDT.


Subscribe


RAP by the numbers
More From The Market Herald
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" Anteotech (ASX:ADO) receives almost $1.2M in R&D tax rebates

Surface chemistry company Anteotech (ADO) has received almost $1.2 million in research and development (R&D) tax rebates for 2020.
Creso Pharma (ASX:CPH) expects TGA’s cannabidiol decision next month

" Creso Pharma (ASX:CPH) expects TGA’s cannabidiol decision next month

Creso Pharma (CPH) says the Therapeutic Goods Administration (TGA) decision, on a major regulatory change for cannabidiol products, is expected next month.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald

" Recce Pharmaceuticals (ASX:RCE) granted overseas R&D kickback

Recce Pharmaceuticals (RCE) is set to pocket a huge kickback from the government’s research and development (R&D) tax rebate scheme.
AnteoTech’s (ASX:ADO) COVID-19 tests detect virus in saliva

" AnteoTech’s (ASX:ADO) COVID-19 tests detect virus in saliva

In a new breakthrough, AnteoTech’s (ADO) COVID-19 test can now detect traces of the virus in saliva.